Table S4. Baseline characteristics of the study patients at CKD Stages 3b or 4 for all predictors, stratified by outcome at 2- and 5-years

|  | 2-years | | 5-years | |
| --- | --- | --- | --- | --- |
| **Characteristic** | **No kidney failure**, N = 2,7101 | **Kidney failure**, N = 881 | **No kidney failure**, N = 2,6161 | **Kidney failure**, N = 1821 |
| **Sex** |  |  |  |  |
| Female | 1,363 (50.3%) | 35 (39.8%) | 1,329 (50.8%) | 69 (37.9%) |
| Male | 1,347 (49.7%) | 53 (60.2%) | 1,287 (49.2%) | 113 (62.1%) |
| **Age (years)** |  |  |  |  |
| Mean (SD) | 75.9 (10.4) | 66.1 (12.1) | 76.2 (10.2) | 66.9 (12.4) |
| Median (IQR) | 77.0 (70.0, 83.0) | 67.0 (59.0, 74.0) | 77.0 (70.0, 83.0) | 67.0 (59.2, 75.0) |
| Range | 23.0, 97.0 | 36.0, 88.0 | 23.0, 97.0 | 26.0, 94.0 |
| **Hypertension** | 1,581 (58.3%) | 55 (62.5%) | 1,517 (58.0%) | 119 (65.4%) |
| **Diabetes Mellitus** | 635 (23.4%) | 39 (44.3%) | 596 (22.8%) | 78 (42.9%) |
| **Persistent albuminuria categories** |  |  |  |  |
| A1 | 1,483 (54.7%) | 11 (12.5%) | 1,469 (56.2%) | 25 (13.7%) |
| A2 | 830 (30.6%) | 30 (34.1%) | 798 (30.5%) | 62 (34.1%) |
| A3 | 397 (14.6%) | 47 (53.4%) | 349 (13.3%) | 95 (52.2%) |
| **GFR categories** |  |  |  |  |
| G3a | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| G3b | 2,171 (80.1%) | 36 (40.9%) | 2,126 (81.3%) | 81 (44.5%) |
| G4 | 539 (19.9%) | 52 (59.1%) | 490 (18.7%) | 101 (55.5%) |
| **CKD KDIGO classification** |  |  |  |  |
| Moderately increased risk | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| High risk | 1,294 (47.7%) | 8 (9.1%) | 1,286 (49.2%) | 16 (8.8%) |
| Very high risk | 1,416 (52.3%) | 80 (90.9%) | 1,330 (50.8%) | 166 (91.2%) |
| **Serum Creatinine (mg/dL)** |  |  |  |  |
| Mean (SD) | 1.7 (0.4) | 2.3 (0.6) | 1.7 (0.4) | 2.2 (0.6) |
| Median (IQR) | 1.6 (1.4, 1.9) | 2.1 (1.8, 2.5) | 1.6 (1.4, 1.8) | 2.1 (1.7, 2.5) |
| Range | 1.1, 3.8 | 1.2, 3.9 | 1.1, 3.8 | 1.2, 3.9 |
| **eGFR using CKD-EPI, ml/min/1.73m2** |  |  |  |  |
| Mean (SD) | 35.9 (7.1) | 28.2 (8.1) | 36.1 (7.0) | 29.0 (8.3) |
| Median (IQR) | 37.6 (31.8, 41.8) | 26.9 (21.6, 34.9) | 37.8 (32.1, 41.9) | 28.3 (22.4, 35.4) |
| Range | 15.0, 45.0 | 15.4, 43.8 | 15.1, 45.0 | 15.0, 44.9 |
| **Albumin-to-creatinine ratio, mg/g** |  |  |  |  |
| Mean (SD) | 306.8 (3,082.4) | 1,172.8 (1,631.1) | 296.0 (3,133.9) | 881.4 (1,272.2) |
| Median (IQR) | 24.6 (6.3, 145.4) | 367.7 (149.1, 1,811.8) | 23.3 (6.1, 131.2) | 334.6 (143.8, 1,076.5) |
| Range | 0.0, 144,870.6 | 2.5, 7,462.7 | 0.0, 144,870.6 | 1.4, 7,462.7 |
| **Urine Albumin (mg/ml)** |  |  |  |  |
| Mean (SD) | 11.7 (33.3) | 56.1 (77.1) | 10.7 (32.2) | 47.4 (64.4) |
| Median (IQR) | 1.5 (0.4, 8.7) | 16.3 (8.9, 66.6) | 1.4 (0.4, 7.7) | 16.5 (8.6, 60.3) |
| Range | 0.0, 658.0 | 0.2, 348.1 | 0.0, 658.0 | 0.1, 348.1 |
| **Urine Creatinine (mg/dl)** |  |  |  |  |
| Mean (SD) | 71.7 (47.4) | 62.1 (33.5) | 71.7 (45.8) | 68.3 (61.8) |
| Median (IQR) | 65.1 (43.7, 85.0) | 55.3 (38.1, 85.0) | 65.4 (43.9, 85.0) | 58.0 (40.1, 85.0) |
| Range | 0.7, 722.1 | 6.4, 218.6 | 0.7, 620.1 | 6.4, 722.1 |
| **Death at 2 years** | 300 (11.1%) | 58 (65.9%) | 300 (11.5%) | 58 (31.9%) |
| **Outcome at 2 years** |  |  |  |  |
| Alive w/o Kidney Failure | 2,410 (88.9%) | 0 (0.0%) | 2,316 (88.5%) | 94 (51.6%) |
| Death w/o Kidney Failure | 300 (11.1%) | 0 (0.0%) | 300 (11.5%) | 0 (0.0%) |
| Kidney Failure | 0 (0.0%) | 88 (100.0%) | 0 (0.0%) | 88 (48.4%) |
| **Death at 5 years** | 726 (26.8%) | 58 (65.9%) | 683 (26.1%) | 101 (55.5%) |
| **Outcome at 5 years** |  |  |  |  |
| Alive w/o Kidney Failure | 1,933 (71.3%) | 0 (0.0%) | 1,933 (73.9%) | 0 (0.0%) |
| Death w/o Kidney Failure | 683 (25.2%) | 0 (0.0%) | 683 (26.1%) | 0 (0.0%) |
| Kidney Failure | 94 (3.5%) | 88 (100.0%) | 0 (0.0%) | 182 (100.0%) |
| 1n (%) | | | | |